Scientific Programme
Thursday, 30 November 2023
Virtual
15:00 - 15:10 CET
Welcome and IntroductionSchnell O (Munich, Germany)
15:10 – 16:50 CET
Update on Clinical Guidelines and network Meta-AnalysesChairs: Groop P-H (Helsinki, Finland), Vandvik PO (Oslo, Norway)
15:10 – 15:25
Management of CKD in 2023: An update of guidelinesGroop P-H (Helsinki, Finland)
15:25 – 15:40
What`s new in the ESC “Diabetes and the Heart” and “Heart Failure” Guidelines 2023Marx N (Aachen, Germany)
15:40 – 15:50
Discussion
15:50 – 16:05
Treatment for Type 2 Diabetes: systematic review and network meta-analysis for the creation of living guidelinesRydén L (Stockholm, Sweden)
16:05 – 16:20
Join the Global Alliance for Living Evidence (GALE)!Tendal Jeppesen B (Copenhagen, Denmark)
16:20 – 16:35
Strengthening the recognition of minority groups in clinical guidelines for diabetesGavin JR (Atlanta, USA)
16:35 – 16:50
Discussion
16:50 – 17:00 CET
Break
17:00 – 18:30 CET
Making sense of Patient-Reported Outcomes (PROs) and why they matterChair: Barnard-Kelly K (Hampshire, UK)
17:00 – 17:15
Consensus statement on PROs - why, how and what does it matter?Barnard-Kelly K (Hampshire, UK)
17:15 – 17:30
IDF perspective on PROsSchwarz P (Dresden, Germany)
17:30 – 17:45
PROs: What are governments doing in this space and how do they influence policy?Taylor B (Tampa, USA)
17:45 – 18:00
Patient´s perspectives on PROsHuntley G (Indianapolis, USA)
18:00 – 18:30
Discussion
18:30 – 18:45 CET
Break
18:45 – 19:45 CET
Keynote lectures: Overcoming boundaries - new options ariseChair: Schnell O (Munich, Germany)
18:45 – 19:05
Multireceptor drugs for obesity: a new emerging universeMüller T (Munich, Germany)
19:05 – 19:15
Discussion
19:15 – 19:35
New horizons for CGM in diabetes: Further building a key pillar of diabetes managementBattelino T (Ljubljana, Slovenia)
19:35 – 19:45
Discussion
Friday, 01 December 2023
Virtual
08:30 – 09:50 CET
Prevention of Type 1 Diabetes and its complicationsChairs: Hummel M (Munich, Germany), Malik RA (Doha, Quatar)
08:30 – 08:45
Type 1 diabetes: early detection and preventive approachesLarsson HE (Lund, Sweden)
08:45 – 09:00
Teplizumab – Delaying the onset of Type 1 DiabetesMathieu C (Leuven, Belgium)
09:00 – 09:15
Treatment strategies for neuropathy in Type 1 DiabetesTesfaye S (Sheffield, UK)
09:15 – 09:30
Preventing and delaying the progression of chronic kidney disease (CKD) in Type 1 Diabetes Groop P-H (Helsinki, Finland)
09:30 – 09:50
Discussion
09:50 – 10:00 CET
Break
10:00 – 11:15 CET
Identification of chronic kidney disease to guide therapeutic decisionChairs: Topsever P (Istanbul, Turkey), Ji L (Bejing, China)
in Cooperation with PCDE
10:00 – 10:15
Self-rated knowledge and competence regarding the management of chronic kidney disease in primary careTopsever P (Istanbul, Turkey)
10:15 – 10:30
Shaping the role of primary care in diagnosis of CKD Itzhak B (Haifa, Israel)
10:30 – 10:45
Identifying people with CKD in primary care: The role of POCT in KDIGO GuidelinesJacob S (Villingen-Schwenningen, Germany)
10:45 – 11:00
Diagnosing CKD with UACR in China - Paving the Way for Effective TreatmentYu X (Tongji, China)
11:00 – 11:15
Discussion
11:15 – 11:30 CET
Break
11:30 – 12:30 CET
Current considerations in the management of CKDChair: Heerspink H (Groningen, Netherlands)
11:30 – 11:50
SGLT-2 inhibitors in CKD: New outcomes to strengthen the bridge to clinical careHeerspink H (Groningen, Netherlands)
11:50 – 12:10
Non-steroidal MRAs: recent and future perspectivesRossing P (Copenhagen, Denmark)
12:10 – 12:30
Discussion
12:30 – 13:15 CET
Heart failure and Cardiovascular RiskChair: Ceriello A (Barcelona, Spain)
12:30 – 12:45
Current and future aspects of heart failure managementKosiborod M (Kansas City, USA)
12:45 – 13:00
CLEAR Outcomes: Reducing cardiovascular mortality and morbidity with bempedoic acidRay KK (London, UK)
13:00 – 13:15
Discussion
13:15 – 13:45 CET
Break
13:45 – 14:30 CET
Cancer – an emerging, yet largely underrecognized important topic in metabolic diseasesChair: Ceriello A (Barcelona, Spain)
13:45 – 14:00
Type 2 Diabetes & Cancer Standl E (Munich, Germany)
14:15 – 14:30
Obesity & Cancer Herzig S (Munich, Germany)
14:15 – 14:30
Joint Discussion
14:30 – 16:15 CET
Diabetes, Obesity and NASH – Discovering the New NowChairs: Forst T (Mannheim, Germany), TBD
14:30 – 14:50
Recent advances in incretin therapyFrias P (San Diego, USA)
14:50 – 15:10
Successful treatment of Type 2 Diabetes and obesity: managing cardiovascular risk and implementing new treatment pathwaysVilsbøll, Tina (Copenhagen, Denmark)
15:10 – 15:30
Diagnosis, prognosis and future treatments options of fatty liver disease Tacke F (Berlin, Germany)
15:30 – 15:50
How to communicate successfully with people who are obeseSnoek F (Amsterdam, Netherlands)
15:50 – 16:15
Discussion
16:15 – 16:30 CET
Break
16:30 – 17:30 CET
Industry´s perspective - panel discussion
17:30 – 18:30 CET
Oral Presentations
18:30 – 18:45 CET
Abstract Awards and ClosingSchnell O (Munich, Germany)